Patents
Literature
23 results about "Dopaminergic" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Dopaminergic means "related to dopamine" (literally, "working on dopamine"), dopamine being a common neurotransmitter. Dopaminergic substances or actions increase dopamine-related activity in the brain. Dopaminergic brain structures facilitate dopamine-related activity. For example, certain proteins such as the dopamine transporter (DAT), vesicular monoamine transporter 2 (VMAT₂), and dopamine receptors can be classified as dopaminergic, and neurons that synthesize or contain dopamine and synapses with dopamine receptors in them may also be labeled as dopaminergic. Enzymes that regulate the biosynthesis or metabolism of dopamine such as aromatic L-amino acid decarboxylase or DOPA decarboxylase, monoamine oxidase (MAO), and catechol O-methyl transferase (COMT) may be referred to as dopaminergic as well. Also, any endogenous or exogenous chemical substance that acts to affect dopamine receptors or dopamine release through indirect actions (for example, on neurons that synapse onto neurons that release dopamine or express dopamine receptors) can also be said to have dopaminergic effects, two prominent examples being opioids, which enhance dopamine release indirectly in the reward pathways, and some substituted amphetamines, which enhance dopamine release directly by binding to and inhibiting VMAT₂.
Composition and Method for Treating Metabolic Disorders
Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.
Owner:VEROSCIENCE LLC
Digital therapeutics and combination therapy for the treatment of parkinsons disease
Provided is a method of digital therapeutics for modulating one or more Parkinson's disease-related markers, symptoms, or disease progression in an individual, on a standalone basis or by combining them with medicinal agents, particularly dopaminergic agents. Also provided are corresponding systems for implementing, delivering, and adapting such therapeutic interventions.
Owner:REMEPY HEALTH LTD
Composition and method for treating metabolic disorders
Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.
Owner:VEROSCIENCE LLC
Digital therapeutics and combination therapy for the treatment of parkinson's disease
PCT designated stageWO2026099869A1Physical therapies and activitiesOrganic active ingredientsPharmacy medicineDopaminergic
Provided is a method of digital therapeutics for modulating one or more Parkinson's disease-related markers, symptoms, or disease progression in an individual, on a standalone basis or by combining them with medicinal agents, particularly dopaminergic agents. Also provided are corresponding systems for implementing, delivering, and adapting such therapeutic interventions.
Owner:REMEPY HEALTH LTD
Method for identifying dopaminergic neurons and progenitor cells
This provides a molecular diagnostic tool useful for the efficient and accurate characterization of the discriminative and functional properties of iPSC-derived dopaminergic neurons. [Solution] A computer-based method for identifying determined dopaminergic progenitor cells within an in vitro population of neural progenitor cells is provided, comprising: receiving a test dataset containing data such as gene expression profile information relating to an in vitro population of neural progenitor cells; querying a gene expression reference database and comparing the test dataset with the gene expression reference database, wherein the gene expression reference database contains gene expression profile information of the desired determined dopaminergic progenitor cells; and outputting a computer-calculated label classification that includes an indication of whether or not the in vitro population of neural progenitor cells contains the determined dopaminergic progenitor cells.
Owner:THE SCRIPPS RES INST +1
In vitro differentiation method of stem cells
Provided are methods for in vitro induced differentiation of embryonic stem cells or pluripotent stem cells into dopaminergic neural progenitor cells, dopaminergic neural precursor cells and / or dopaminergic neurons. Also provided are media for use in the method, cell populations obtained using the method, and the use of the obtained cell populations in the prevention and / or treatment of diseases and / or dysfunctions associated with dopaminergic neuron degenerative disorders.
Owner:XELLSMART BIOMEDICAL (SUZHOU) CO LTD
Method for improving reverse electron transfer rate and energy metabolism level of shewanella single cell by preparing artificial conductive path
Shewanella bacteria are mode electrochemically active bacteria and have bidirectional electron transfer capability, but the reverse electron transfer rate is slower. In order to solve the problem, the invention discloses a method for synchronously constructing an artificial conductive path in shewanella bacteria attachment so as to improve the electron transfer rate of a bacteria-electrode interface and the energy metabolism activity of bacteria. By utilizing the method, after dopamine is subjected to in-situ electropolymerization in the adsorption process of shewanella tamariscina PV-4, polydopamine is formed in a bacterium-electrode interface area, and the current transferred by reverse electrons is improved by 3.46 times. Due to the fact that polydopamine can serve as an artificial conductive path, the reverse electron transfer capacity of shewanella single cells is improved, and the intracellular energy metabolism level is improved through faster electron transfer.
Owner:BEIJING INST OF TECH
Methods and compositions for selective generation of dopaminergic precursors
The present invention provides methods of transdifferentiating a somatic cell, e.g., a fibroblast, to an induced dopaminergic precursor cell (iDP) in vitro. The methods include ectopically expressing genes of (1) one or both of Brn2 and Brn4, or a variant thereof, (2) Sox2, or a variant thereof, and (3) one or both of Foxa2 and Lmx1a, or a variant thereof, in the somatic cell, and methods for treating a neurodegenerative disease, such as Parkinson's disease, with the iDP.
Owner:TONGJI UNIV +1
Therapeutic agent for non-motor symptoms associated with parkinson's disease
The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease; and a method for treating the aforesaid symptoms or preventing the recurrence of the same. A compound represented by formula (1) [wherein each symbol is as defined in the description] or a pharmaceutically acceptable salt thereof can exhibit an effect of treating serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease and / or an effect of preventing the recurrence of the same.
Owner:NEUROINNOVATECH APS
Method of treatment of CNS disorders
The invention comprises a method of treatment of CNS disorders by a pharmaceutical agent exhibiting combined noradrenergic, serotonergic or dopaminergic reuptake transporter inhibitory and μ-opioid agonistic activity.
Owner:SUPERNUS PHARMACEUTICALS INC
Method for producing nerve cells
PCT designated stageWO2026141672A1Induced pluripotent stem cellLPA Receptors
The present application provides a method for producing, from pluripotent stem cells, neural progenitor cells of the midbrain floor plate region or dopaminergic neural progenitor cells, the method comprising (1) inducing differentiation of pluripotent stem cells into neural progenitor cells of the midbrain floor plate region, and optionally (2) inducing differentiation of the neural progenitor cells of the midbrain floor plate region, which are obtained by the differentiation induced in (1), into dopaminergic neural progenitor cells, wherein all or part of the differentiation induced in (1) includes culturing the cells in a medium containing an agonist for LPA receptor.
Owner:RACTHERA CO LTD +1
Dopaminergic imaging to predict treatment response in mental illness
A neuroimaging-based approach to predict treatment response in mental disorders by acquiring and analysing brain PET dopamine measures from patients. The method uses a short, simplified protocol for [18F]FDOPA brain PET imaging adapted for clinical practice. Individual [18F]FDOPA brain PET data are then quantified with a fully-automated analysis pipeline to extract information on the dopamine function of the subject. This information coupled with clinical information is run through a prediction algorithm to identify those patients whose illness will not respond to conventional antipsychotics.
Owner:KINGS COLLEGE LONDON
Nerve cell with conditional immune escape function and suicide function, and establishment method and application thereof
The invention provides a nerve cell with a conditional immune escape function and a suicide function as well as an establishment method and application of the nerve cell. The invention discloses a space-time specific regulation element which can form a space-time specific promoter to regulate the expression of a target gene in a dopaminergic nerve precursor stage (mDAP). In addition, the invention also discloses a modified induced pluripotent stem cell and a nerve cell which is obtained by differentiation and has a conditional immune escape function and a suicide function. The cell can automatically trigger immune escape in the early stage of the dopamine energy precursor, and synchronously has a drug controllable self-destruction function.
Owner:SHANGHAI YUANVORE MEDICINE TECHNOLOGY CO LTD
Use of casein phosphopeptides to facilitate modulation of dopaminergic neurons
The invention belongs to the technical field of food, and relates to novel application of casein phosphopeptides, in particular to application of the casein phosphopeptides in preparation of food beneficial to regulation of dopaminergic neurons of organisms, and regulation of the dopaminergic neurons of the organisms comprises enhancement of the strength of the dopaminergic neurons and / or enhancement of the strength of the dopaminergic neurons. Neurotransmitters and metabolites beneficial to operation of a dopamine energy system are regulated and controlled.
Owner:HEILONGJIANG FEIHE DAIRY CO LTD
Methods and compositions for dosing a cell therapy for parkinson's disease
PCT designated stageWO2026064194A1Nervous disorderUnknown materialsInduced pluripotent stem cellMidbrain
Provided are methods for administering allogeneic induced pluripotent stem cells (iPSC)-derived midbrain dopaminergic progenitors to a subject for treatment of Parkinson's disease (PD). The midbrain dopaminergic progenitor cells are administered to 5 trajectories, each with 8 depositional sites, per putamen. Patients are operated on using a trans-frontal approach with an entry point near the coronal suture. Also provided are compositions and articles of manufacture for use in the methods.
Owner:KENAI THERAPEUTICS INC +1
Dose regimens for use of LY3154207 in the treatment of dopaminergic CNS disorders
The present invention relates to dosing regimens and methods of using LY3154207, also described as 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2 (1H)-yllethanone, and / or pharmaceutical compositions thereof, for treatment of dopaminergic central nervous system disorders. Dopaminergic CNS disorders of the present dosing regimen methods include Parkinson's Disease, Alzheimer's Disease, Lewy body dementia (LBD), Vascular Dementia, Schizophrenia, ADHD, Depression, Autism, chronic musculoskeletal pain, fibromyalgia, cognitive impairment disorders, sleep disorders, excessive daytime sleepiness, narcolepsy, shift work disorder, traumatic brain injury, chronic traumatic encephalopathy, obesity and appetite regulation, mood disorders, lethargy, apathy, and addiction disorders.
Owner:ELI LILLY & CO
Dopaminergic neural precursor cell cryo- and cryopreservation methods
ActiveCN117502429BSomaDopaminergic
The application provides a dopamine nerve precursor cell freezing solution which is free of serum and animal-derived components, and contains a clinical-grade freezing base solution dextran sodium chloride injection, a non-osmotic cryoprotectant injection-grade human serum albumin (HSA) and an osmotic cryoprotectant injection-grade DMSO, wherein the mass concentration of the non-osmotic cryoprotectant is less than 10% and the mass concentration of the osmotic cryoprotectant is less than 15%, and the dopamine nerve precursor cell freezing solution further contains an additive capable of improving the recovery rate of dopamine nerve precursor cells. The dopamine nerve precursor cell freezing solution provided by the application has simple and clear components, can greatly reduce the damage to cells during the freezing process, significantly improve the recovery rate of cells after resuscitation, maintain the purity and the potential for continuous differentiation of the cells, and is suitable for the storage of clinical-grade dopamine nerve precursor cells at different differentiation stages.
Owner:ANHUI ZHONGSHENG TRACEABLE BIOTECHNOLOGY CO LTD
Anti-dat antibodies and compositions thereof
An anti-DAT antibody which is formed from a gene comprising SEQ ID No:2 after transcription and translation. The anti-DAT antibody of the present invention can be made into a composition capable of crossing the blood-brain barrier, and specifically binding to dopamine nerve cells, and achieving excellent efficacy in reducing the accumulation of α-syn in the striatum and delaying the course of Parkinson's disease.
Owner:CHINA MEDICAL UNIVERSITY(TW)
3-(4-(4-arylpiperazin-1-yl) butyl-4H-chromen-4-one, process of preparation and its therapeutic application
The present invention relates a compound of general formula 1: wherein: R1 represents one or more identical or different substituent(s) on the benzene ring, each representing, independently, a hydrogen atom or a halogen atom, or a C1-4alkoxy group or an OH group, or a C1-4alkyl group or an -0(CH2)n0- group in which n = 1 or 2. -R2 represents a hydrogen atom or a C1-4alkyl group. -A and B represent, independently, either a nitrogen atom or a carbon atom. R3 represents a hydrogen atom or one or more identical or different substituent(s) selected from the group composed of : a halogen atom, a C1-4alkyl group, a C1-4alkoxy or C1-4thioalkoxy group, an -0(CH2)n0- group in which n = 1 or 2, an NO2 group, an NHSO2R4 group, an NHR5 group, an OH group, a C1-4haloalkyl group, a CN group, a C1-4alkoxycarbonyl group, a C1-4alkylcarbonyl group, a C1-4hydroxyalkyl group and a benzyl or phenyl substituent optionally substituted by a C1-4alkoxy or a C1-4alkyl group or a halogen atom, their pharmaceutical composition and their application as D3 dopaminergic ligands as a medicament for disorders of the central nervous system.
Owner:PIERRE FABRE MEDICAMENT SAS
Method and kit for characterizing dopaminergic progenitor cells obtained by differentiating pluripotent stem cells
This disclosure provides a method and kit for analyzing compositions of human floorplate mesencephalic dopaminergic (mesDA) progenitor cells that are obtained, for example, by differentiating embryonic stem cells. The mesDA progenitors are characterized using the positive markers FOXA2. OTX2, and optionally NKX2. 1. in combination with the negative markers OCT3 / 4, and optionally PAX6, and SOXI. Cells with an appropriate protein expression profile have therapeutic potential for restoring the function of dopaminergic neurons in conditions such as Parkinson's Disease.
Owner:MILTENYI BIOTEC BV & CO KG
L-DOPA and / or DOPA decarboxylse inhibitors conjugated to sugar for the treatment of dopamine-responsive disorders
The present invention provides conjugates comprising a sugar such as mannitol and one or more L-DOPA and / or DOPA decarboxylse inhibitors including, inter alia, L-DOPA, carbidopa, benserazide, or a combination thereof, wherein the sugar is conjugated to the carboxyl group of the L-DOPA and / or DOPA decarboxylse inhibitor / s) via a hydroxyl group of the sugar. The present invention further provides related pharmaceutical compositions and methods of producing the conjugates, as well as methods of use for treating medical disorders responsive to dopamininergic stimulation such as movement disorders including, inter alia, Parkinson's Disease.
Owner:BG NEGEV TECHNOLOGIES & APPLICATIONS LTD
Integration of molecular mechanisms in the striatum as a combination drug strategy for the treatment of psychiatric and neurological disorders in which anhedonia or motivation-related dysfunction exists
The present invention relates to the use of a combination of two or more of a D2 agonist, an adenosine A2A receptor antagonist, a histamine H3 antagonist or inverse agonist, a mGluR5 receptor antagonist, or a nicotinic α4-β2 and / or α7 receptor agonist to increase D2 dopaminergic molecular signaling in the striatum for the treatment of psychiatric or neurological disorders in which anhedonia or motivation-related dysfunction exists (such as major depressive disorder, bipolar I or II disorder, post-traumatic stress disorder, addiction, anhedonia or motivation-related aspects of schizophrenia (e.g. negative symptoms) and Parkinson's disease (e.g. non-motor features such as depression and apathy)).
Owner:ALTO NEUROSCIENCE INC
Universal human induced pluripotent stem cells, mDAP / mDA cells and applications
The present application relates to the technical field of genetic engineering and cell biology, and particularly relates to a universal human induced pluripotent stem cell, PD-L1 The promoter is inserted into a short enhancer sequence, the short enhancer sequence has the characteristics of enhancing the expression of PD-L1 when being differentiated into dopaminergic neural precursor cells or dopaminergic neuron cells, and the short enhancer sequence is selected from any one of TSE012, TSE026, TSE053, TSE075 and TSE089. The present application also relates to a ready-to-use mDAP / mDA cell and application, has cell type-specific immune escape, only when the cell is differentiated into mDAP / mDA, the expression of immune rejection genes PD-L1 and CTLA4 is started, has little influence on genomic stability, and in-situ activation of gene expression is realized.
Owner:SHANGHAI YUANVORE MEDICINE TECHNOLOGY CO LTD